Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Alison Friedmann, M.D.


This page shows the publications co-authored by Alison Friedmann and Vinayak Venkataraman.
Connection Strength

  1. Secondary histiocytic sarcoma with BRAFV600E mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapy. Pediatr Blood Cancer. 2021 10; 68(10):e29166.
    View in: PubMed
    Score: 0.940
  2. Secondary histiocytic sarcoma with BRAFV600E mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinib. Pediatr Blood Cancer. 2020 05; 67(5):e28200.
    View in: PubMed
    Score: 0.858
  3. Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma. Oncologist. 2021 07; 26(7):e1263-e1272.
    View in: PubMed
    Score: 0.058
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.